Clinical trials: Radiotherapy Side Effects
Cardiac Toxicity, Malignant Neoplasm
MRI in Detecting Heart Damage in Patients With Cancer Receiving Chemotherapy With Exercise Capacity Addendum
This trial studies how well magnetic resonance imaging (MRI) works in detecting heart damage in patients with cancer receiving chemotherapy.
- Conditions
- Cardiac Toxicity, Malignant Neoplasm, Breast Cancer
- Trial name
- NCT01719562
- Testing
- Magnetic resonance imaging, Physical Activity, Healthy Living
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Wake Forest University Health Sciences
Osteosarcoma, Nephrotoxicity
Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy
Osteosarcoma is the most common type of bone cancer in children, adolescents and young adults. Treatment with surgery and a combination of three conventional chemotherapy drugs can cure nearly two-thirds patients with…
- Conditions
- Osteosarcoma, Nephrotoxicity, Ototoxicity
- Trial name
- NCT01848457
- Testing
- Pantoprazole, High-dose methotrexate infusion duration
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Children's Hospital of Philadelphia
Cardiotoxicity, Breast Cancer
PROactive Evaluation of Function to Avoid CardioToxicity
This study is intended to evaluate the ability of an intramyocardial strain analysis package with cardiac MRI to assist in the early detection and management of cardiotoxicity from therapeutics used to treat cancer.
- Conditions
- Cardiotoxicity, Breast Cancer, Lymphoma, Sarcoma
- Trial name
- PROACT (NCT03862131)
- Testing
- MyoStrain®
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Washington University School of Medicine
Cardiac Toxicity, Chemotherapeutic Agent Toxicity
Cardiac Magnetic Resonance Imaging in Patients With Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin
RATIONALE: Diagnostic procedures, such as cardiac magnetic resonance imaging, may help doctors detect early changes in the heart caused by chemotherapy.
- Conditions
- Cardiac Toxicity, Chemotherapeutic Agent Toxicity, Lymphoma
- Trial name
- NCT00577798
- Testing
- contrast-enhanced magnetic resonance imaging
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Head and Neck Neoplasms
Image Guided Adaptive Radiotherapy in the Head-and-neck Region
Aim of this study is the clinical evaluation of an image-guided adaptive radiotherapy concept. This involves the adaption of the radiotherapy treatment plan according to changes in tissues and variations in patients position and…
- Trial name
- BART (NCT02545322)
- Testing
- Follow-up CT scans during week 3 and week 5 of treatment
- Volunteers
- 18 people
- Sponsor
- Medical University of Graz
Breast Cancer, Heart Disease
STOP Heart Disease in Breast Cancer Survivors Trial
The purpose of this study is to to examine the effects of atorvastatin, a type of statin, on changes to the heart among women undergoing breast cancer treatment.
- Conditions
- Breast Cancer, Heart Disease, Cardiotoxicity, Myocardial Dysfunction
- Trial name
- STOP (NCT02674204)
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Cedars-Sinai Medical Center
Ototoxicity
SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity
The primary objective of this study is to determine the safety and efficacy of SPI-1005 treatment in CF patients with active pulmonary exacerbation that are receiving an IV course of tobramycin, determined by comparing hearing…
- Trial name
- NCT02819856
- Testing
- SPI-1005 Ebselen 200mg Capsule x1, SPI-1005 Ebselen 200mg Capsule x2, SPI-1005 Ebselen 200mg Capsule x3
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Sound Pharmaceuticals, Incorporated
Ototoxicity, Unspecified Adult Solid Tumor
Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin
RATIONALE: Alpha-lipoic acid may prevent or lessen hearing loss caused by cisplatin. PURPOSE: This randomized clinical trial is studying the effectiveness of alpha-lipoic acid in preventing hearing loss in cancer patients…
- Trial name
- NCT00477607
- Testing
- alpha-lipoic acid, Audiology, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- US Department of Veterans Affairs
Breast Cancer
Acute Exercise Cardioprotection From Doxorubicin
In rodents, a single bout of exercise prior to injection of a chemotherapy agent used to treat breast cancer prevents or attenuates a number of markers of cardiac injury.
- Trial name
- NCT02006979
- Testing
- exercise
- Where
- Canada
- Volunteers
- 27 people
- Sponsor
- University of British Columbia
Glioblastoma Multiforme
UNITE Study: Understanding New Interventions With GBM ThErapy
The objective of this study was to evaluate the effect of several ophthalmologic prophylactic treatment strategies for the management of ocular side effects (OSEs) in participants with epidermal growth factor receptor…
- Trial name
- NCT03419403
- Testing
- Steroid eye drops, Vasoconstrictor eye drops, Cold compress
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 40 people
- Sponsor
- AbbVie
Cardiotoxicity
Staccato Prochlorperazine Thorough QT/QTc
To assess the safety of Staccato Prochlorperazine on cardiac repolarization (QTc interval duration) at 2 dose levels compared to placebo in healthy volunteers.
- Trial name
- NCT00543062
- Testing
- Inhaled prochlorperazine 5 mg, Inhaled prochlorperazine 10 mg, Oral moxifloxacin
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Alexza Pharmaceuticals, Inc.
Prostate Cancer
A Feasibility Study Followed By A Randomized Phase II Study Of Yoga For Radiation Therapy Side Effects In Prostate Cancer
This study will ascertain the feasibility and effect of Eischens yoga interventions on radiation related fatigue, sexual dysfunction and urinary incontinence in stage I /II prostate cancer patients undergoing radiotherapy with…
- Trial name
- NCT02135653
- Testing
- Radiotherapy, Eischens Yoga
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Cancer, Cardiac Toxicity
Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab
RATIONALE: Lisinopril or Coreg CR®, may help reduce side effects caused by trastuzumab. It is not yet known whether lisinopril or Coreg CR® are more effective than a placebo in reducing side effects caused by trastuzumab.
- Trial name
- NCT01009918
- Testing
- Coreg CR®, lisinopril
- Where
- 174 sites in United States
- Volunteers
- 468 people
- Sponsor
- University of South Florida
Central Nervous System Tumors, Brain Tumors
A Study for Image-Guided Radiation Therapy in Pediatric Brain Tumors and Side Effects
The purpose of the study was to determine if treating a limited volume of normal tissue surrounding the tumor or tumor bed using conformal radiation therapy would achieve similar rates of disease control compared to standard…
- Trial name
- NCT00187226
- Testing
- Radiation Therapy
- Where
- United States
- Volunteers
- 361 people
- Sponsor
- St. Jude Children's Research Hospital
Radiation Necrosis
Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI)
To assess the overall safety and efficacy of intra-arterial (IA) bevacizumab for the treatment of radiation necrosis. A single 2.5 mg/kg dose of bevacizumab will be given intra-arterially after osmotic blood-brain-barrier…
- Trial name
- LIBERTI (NCT02819479)
- Testing
- 25% Mannitol, Low-dose Intra-arterial Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Norton Healthcare
Irradiation; Adverse Effect
Measurement of the Radiation Dose Cuticles Using Electron Paramagnetic Resonance (EPR)
This study is to test the effectiveness a new method (called EPR dosimetry) that could be used to measure radiation doses to fingernails that occur as a result of unplanned exposure to radiation, such as might occur from the…
- Trial name
- NCT00904189
- Testing
- Standard of care given for treatment of cancer
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Rochester
Prostate Cancer
Protection of Rectum From High Radiation Doses
The purpose of this study is to evaluate the usefulness of diluted DuraSeal product as a spacer between prostate and rectum in prostate cancer low dose brachytherapy.
- Trial name
- NCT01601691
- Testing
- DuraSeal
- Where
- Finland
- Volunteers
- 10 people
- Sponsor
- University of Oulu
Breast Cancer, Cardiac Toxicity
Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00436566
- Testing
- trastuzumab, cyclophosphamide, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- Mayo Clinic
Breast Cancer
Using the Active Breathing Control Device to Reduce Radiation Side Effects to Critical Structures in Breast Cancer
The purpose of this study is to evaluate the use of a device that helps coordinate the breathing cycle in the radiation treatment of the breast in order to minimize the radiation dose to the normal structures around the breast.
- Trial name
- NCT00328783
- Testing
- Active Breathing Coordinator (ABC), Radiation Therapy
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Breast Cancer
An Integrated Consent Model Study to Compare Two Standard of Care Schedules for Monitoring Cardiac Function in Patients Receiving Trastuzumab for Early Stage Breast Cancer
Several large adjuvant trastuzumab trials have demonstrated improved overall survival in participants with early stage breast cancer, with a 33% decrease in risk of death.
- Trial name
- OTT 15-05 (NCT02696707)
- Testing
- LVEF 3 month, LVEF 4 month
- Where
- 4 sites in Canada
- Volunteers
- 200 people
- Sponsor
- Ottawa Hospital Research Institute